Seismic Therapeutic
Chapel Hill, NC, United States
John is a rheumatologist and immunologist with over 25 years of experience in academic medicine and the biotechnology industry. His research has focused on novel therapies for inflammatory and fibrotic diseases. John is the Chief Medical Officer and Head of R&D at Seismic Therapeutic. Most recently, he was the CMO of Pandion Therapeutics, which was acquired by Merck in 2021. He previously was SVP and Inflammation Therapeutic Area Head at Gilead Sciences where he oversaw the clinical development of over a dozen new drug programs.
Before moving to industry, John was a tenured Associate Professor of Medicine at Duke University and Associate Professor at the Duke-National University of Singapore Graduate Medical School. While at Duke he was instrumental in the Phase 1-3 development of Krystexxa which is approved for patients with refractory gout. In addition, he served as Associate Director of the Duke Clinical Research Institute and Director of Duke's Global Proof of Concept Research Unit Network in the US, Singapore and India.
An undergraduate from Bucknell University, John received his medical and scientific education at Drexel University, and clinical training at Duke. He is a fellow of the ACR, the AAAAI, and the ACP. John is an Adjunct Professor of Medicine at Duke University and maintains clinical privileges at the Durham VA Medical Center. He has authored over 100 scientific publications, and also serves on the board of directors of Neutrolis, Inc; and CARRA.
Disclosure information not submitted.
Saturday, November 12, 2022
1:00 PM – 2:00 PM Eastern Time
